Results of using L-ornitin-L-aspartate in the treatment of hepatic encephalopathy in liver transplantation

The aim was to study the results of using various treatment regimens for hepatic encephalopathy for patients with liver cirrhosis before and after liver transplantation and the effect on the incidence and severity of hepatic encephalopathy in the perioperative period, and on the posttransplantation course.
Material and methods. Fifty four patients with cirrhosis of various etiologies and the presence of significant hepatic encephalopathy undergoing living donor liver transplantation were included in the study. In the comparison group, patients took lactulose and rifaximin. In the main group, patients took lactulose and rifaximin in combination with L-ornithine-L-aspartate in the preoperative period, and L-ornithine-L-aspartate after liver transplantation for 5 days.
Results. The use of L-ornithine-L-aspartate in the complex therapy of hepatic encephalopathy led to significantly reduced time of performing the Number Connection Test, the improvement of cognitive functions in patients by the Montreal Cognitive Assessment, a decreased incidence of stage II–III hepatic encephalopathy and an increased incidence of stage 0-I hepatic encephalopathy in the preoperative period. In the postoperative period, patients of the main group showed a rapid decrease in the severe stages of hepatic encephalopathy (stage II–III) towards less severe forms (stage 0–I) on the 3rd, 5th and 7th days after liver transplantation, and also a faster recovery of cognitive functions, an earlier adequate recovery of consciousness, muscle tone, an earlier possibility of extubation, a shorter length of stay in the intensive care unit, and a decreased postoperative hospital length of stay relatively to the patients of the comparison group.
Conclusion. The use of L-ornithine-L-aspartate in the combination therapy for hepatic encephalopathy in the peritransplantation period leads to a significant decrease of the incidence and severity of hepatic encephalopathy, accelerates rehabilitation of patients, reduces postoperative hospital length of stay.

1. Pavlov ChS, Damulin IV, Ivashkin VT. Hepatic encephalopathy: pathogenesis, clinical features, diagnosis, therapy. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(1):44–53. (In Russ.).

2. Poluhina AV, Hajmenova TYu, Vinnickaya EV. Hepatic encephalopathy: a problem of pharmacotherapy. Meditsinskiy sovet. 2018;(3):43-48. (In Russ.).

3. Plotnikova EYu, Baranova EN, Maksimov SA. The relationship of hepatic encephalopathy with zinc in liver diseases, diagnosis and treatment. Gastroenterology. 2017;(4):33–40. (In Russ.).

4. Weissenborn K. Hepatic encephalopathy: definition, clinical grading and diagnostic. Drugs. 2019;79(Suppl 1):5–9. PMID: 30706420 https://doi.org/10.1007/s40265-018-1018-z

5. Elwir S, Rahimi RS. Hepatic encephalopathy: an update on the pathophysiology and therapeutic options. J Clin Transl Hepatol. 2017;5(2):142–151. PMID: 28660152 https://doi.org/10.14218/JCTH.2016.00069

6. Patidar KR, Bajaj JS. Covert and overt hepatic encephalopathy: diagnosis and management. Clin Gastroenterol Hepatol. 2015;13(12):2048–2061. PMID: 26164219 https://doi.org/10.1016/j.cgh.2015.06.039

7. Suraweera D, Sundaram V, Saab S. Evaluation and management of hepatic encephalopathy: current status and future directions. Gut Liver. 2016;10(4):509–519. PMID: 27377741 https://doi.org/10.5009/gnl15419

8. Nikonov EL, Aksenov VA. Hepatic encephalopathy. Dokazatel'naya gastroenterologiya. 2017;(4):25–31. (In Russ.).

9. Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the study of liver diseases and the European Association for the study of the liver. Hepatology. 2014;60(2):715–735. PMID: 25042402 https://doi.org/10.1002/hep.27210

10. Leise MD, Poterucha JJ, Kamath PS, Kim WR. Management of hepatic encephalopathy in the hospital. Mayo Clin Proc. 2014;89(2):241–253. PMID: 24411831 https://doi.org/10.1016/j.mayocp.2013.11.009

11. Salehi S, Tranah TH, Lim S, Heaton N, Heneghan M, Aluvihare V, et al. Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list. Aliment Pharmacol Ther. 2019;50(4):435–441. PMID: 31169941 https://doi.org/10.1111/apt.15326

12. Butterworth RF, McPhall MJW. L-Ornithine L-Aspartate (LOLA) for hepatic encephalopathy in cirrhosis: results of randomized controlled trials and meta-analyses. Drugs. 2019;79(Suppl 1):31–37. PMID: 30706425 https://doi.org/10.1007/s40265-018-1024-1

13. Butterworth RF, Kircheis G, Hilger N, McPhail MJW. Efficacy of L-Ornithine L-Aspartate for the treatment of hepatic encephalopathy and hyperammonemia in cirrhosis: systematic review and meta-analysis of randomized controlled trials. J Clin Exp Hepatol. 2018;8(3):301–313. PMID: 30302048 https://doi.org/10.1016/j.jceh.2018.05.004

14. Artemiev AI, Naidenov EV, Zabezhinsky DA, Gubarev KK, Kolyshev IYu, Rudakov VS, et al. Liver transplantation for unresectable echinococcus alveolaris. Sovremennye tekhnologii v meditsine. 2017;9(1):123–128. (In Russ.).

15. Voskanyan SE, Artemyev AI, Sushkov AI, Kolyshev IY, Rudakov VS, Shabalin MV, et al. Vascular reconstruction and outcomes of 220 adult-to-adult right lobe living donor liver transplantations. Almanac of Clinical Medicine. 2018;46(6):598–608. (In Russ.).

16. Voskanyan SE, Artemiev AI, Naidenov EV, Zabezhinsky DA, Chuchuev ES, Rudakov VS, et al. Transplant technologies for surgical treatment of the locally advanced hepatic alveolar echinococcosis with invasion of the main vessels. Annaly khirurgicheskoy gepatologii. 2016;21(2):25–31. (In Russ.).

17. Voskanyan SE, Naidenov EV, Artemiev AI, Zabezhinsky DA, Rudakov VS, Zhurbin AS, et al. Comparative results of use of the hepatoprotective drugs in the prevention of the liver failure at extensive liver resections. Hirurgija. Zhurnal im. N.I. Pirogova. 2016;(9):71–75. (In Russ.).

18. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy – definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35(3):716–721. PMID: 11870389 https://doi.org/10.1053/jhep.2002.31250

19. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V. The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699. PMID: 15817019 https://doi.org/10.1111/j.1532-5415.2005.53221.x

20. Rebrova OYu. Once again of the quality of statistical analysys in medical publications: current status of the problem, recommendations, peer reviewing. Medical technologies. Assessment and choice. 2014;15(1):8–10. (In Russ.).

21. Kornerup LS, Pflugrad H, Weissenborn K, Vilstrup H, Dam G. Cognitive impairment after liver transplantation: residual hepatic encephalopathy or posttransplant encephalopathy? Hepat Med. 2019;11:41–46. PMID: 31040728 https://doi.org/10.2147/HMER.S144667

22. Hopp A-E, Dirks M, Petrusch C, Goldbecker A, Tryc AB, Barg-Hock H, et al. Hepatic encephalopathy is reversible in the long term after liver transplantation. Liver Transpl. 2019;25(11):1661– 1672. PMID: 31437344 https://doi.org/10.1002/lt.25626

23. Pflugrad H, Tryc AB, Goldbecker A, Barg-Hock H, Strassburg C, Klempnauer J, et al. Cerebral metabolite alterations in patients with posttransplant encephalopathy after liver transplantation. PLoS ONE. 2019;14(8):e0221626. PMID: 31442276 https://doi.org/10.1371/journal.pone.0221626

24. Lucidi C, Corradini SG, Abraldes JG, Merli M, Tandon P, Ferri F, et al. Hepatic encephalopathy expands the predictivity of model for end-stage liver disease in liver transplant setting: evidence by means of 2 independent cohorts. Liver Transpl. 2016;22(10):1333–1342. PMID: 27434824 https://doi.org/10.1002/lt.24517

25. Weiss N, Thabut D. Neurological complications occurring after liver transplantation: role of risk factors, hepatic encephalopathy, and acute (on chronic) brain injury. Liver Transpl. 2019;25(3):469–487. PMID: 30697911 https://doi.org/10.1002/lt.25420